Co-spray drying of ciprofloxacin and colistin and the uses thereof
AssigneePurdue Research Foundation
InventorsQi Zhou, Nivedita Shetty
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to a combination dry powder inhaler (DPI) formulation of Ciprofloxacin and Colistin through co-spray drying, particularly to a co-sprayed colistin and Ciprofloxacin dry powder inhaler for the treatment of various bacterial infections. Methods of use and composition matters are within the scope of this disclosure.
Claims19
A process for manufacturing a dry powder composition consisting of leucine, dual antibiotics of a polymycin and a quinolone, comprising the steps of
- a. dissolving leucine, a polymyxin compound and a quinolone compound, or a pharmaceutically acceptable salts thereof, respectively, in an aqueous or an organic medium to prepare a solution;
- b. adding one or more pharmaceutically acceptable excipients to said solution;
- and
- c. spray-drying to afford said dry powder composition of dual antibiotics with an improved inhalable fraction of said antibiotics and an increased physical stability and aerosolization stability as compared with quinolone alone.
A pharmaceutical composition consisting of leucine and dual antibiotics of a polymycin and a quinolone manufactured according to a process of:
- a. dissolving leucine, said polymycin and said quinolone, or pharmaceutically acceptable salts thereof, in an aqueous or an organic medium to prepare a solution;
- b. adding one or more pharmaceutically acceptable excipients to said solution;
- and
- c. spray-drying to afford said pharmaceutical composition of dual antibiotics with an improved inhalable fraction of said antibiotics and an increased physical stability and aerosolization stability as compared with quinolone alone.
A method for treating a patient with a bacterial infection comprising the step of administering a therapeutically effective amount of a pharmaceutical composition to a patient in need of relief from said infection, wherein said pharmaceutical composition consisting of leucine, a quinolone, and a polymycin is manufactured according to a process comprising the steps of
- a. dissolving said leucine, polymycin and quinolone antibiotics, or pharmaceutically acceptable salts thereof, in an aqueous or an organic medium to prepare a solution;
- b. adding one or more pharmaceutically acceptable excipients to said solution;
- and
- c. spray-drying to afford said pharmaceutical composition of dual antibiotics of said polymycin and said quinolone with an improved inhalable fraction of said antibiotics and an increased physical stability and aerosolization stability as compared with quinolone alone.
Dependencies are inferred from the claim text.